A citation-based method for searching scientific literature

Nicoletta Machin, Margaret V Ragni. J Blood Med 2018
Times Cited: 44







List of co-cited articles
422 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
K John Pasi, Savita Rangarajan, Pencho Georgiev, Tim Mant, Michael D Creagh, Toshko Lissitchkov, David Bevan, Steve Austin, Charles R Hay, Inga Hegemann,[...]. N Engl J Med 2017
194
56

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
Alfica Sehgal, Scott Barros, Lacramioara Ivanciu, Brian Cooley, June Qin, Tim Racie, Julia Hettinger, Mary Carioto, Yongfeng Jiang, Josh Brodsky,[...]. Nat Med 2015
178
36

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli, M Elisa Mancuso, Christophe Schmitt, Victor Jiménez-Yuste, Christine Kempton, Christophe Dhalluin,[...]. N Engl J Med 2018
291
29

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Johannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, Christophe Schmitt, Michael U Callaghan, Guy Young, Elena Santagostino, Rebecca Kruse-Jarres, Claude Negrier, Craig Kessler,[...]. N Engl J Med 2017
478
29

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
David Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, Chih-Chao Yang, Mitsuharu Ueda, Arnt V Kristen, Ivailo Tournev, Hartmut H Schmidt, Teresa Coelho, John L Berk,[...]. N Engl J Med 2018
27

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
Jayaprakash K Nair, Jennifer L S Willoughby, Amy Chan, Klaus Charisse, Md Rowshon Alam, Qianfan Wang, Menno Hoekstra, Pachamuthu Kandasamy, Alexander V Kel'in, Stuart Milstein,[...]. J Am Chem Soc 2014
518
25

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
P Chowdary, S Lethagen, U Friedrich, B Brand, C Hay, F Abdul Karim, R Klamroth, P Knoebl, M Laffan, J Mahlangu,[...]. J Thromb Haemost 2015
155
25

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.
Amy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita,[...]. Blood 2019
50
25

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
A Fire, S Xu, M K Montgomery, S A Kostas, S E Driver, C C Mello. Nature 1998
20

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
K John Pasi, Savita Rangarajan, Nina Mitchell, Will Lester, Emily Symington, Bella Madan, Michael Laffan, Chris B Russell, Mingjin Li, Glenn F Pierce,[...]. N Engl J Med 2020
152
20

Guidelines for the management of hemophilia.
A Srivastava, A K Brewer, E P Mauser-Bunschoten, N S Key, S Kitchen, A Llinas, C A Ludlam, J N Mahlangu, K Mulder, M C Poon,[...]. Haemophilia 2013
18

AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Savita Rangarajan, Liron Walsh, Will Lester, David Perry, Bella Madan, Michael Laffan, Hua Yu, Christian Vettermann, Glenn F Pierce, Wing Y Wong,[...]. N Engl J Med 2017
353
18

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Takehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei, Atsushi Muto, Tetsuo Kojima, Tetsuhiro Soeda, Kazutaka Yoshihashi, Yukiko Okuyama-Nishida, Hiroyuki Saito, Hiroyuki Tsunoda,[...]. Nat Med 2012
265
18



Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Steven W Pipe, Midori Shima, Michaela Lehle, Amy Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S Key, Agnès Portron, Christophe Schmitt, Maria Podolak-Dawidziak,[...]. Lancet Haematol 2019
136
18

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J Manco-Johnson, Thomas C Abshire, Amy D Shapiro, Brenda Riske, Michele R Hacker, Ray Kilcoyne, J David Ingram, Michael L Manco-Johnson, Sharon Funk, Linda Jacobson,[...]. N Engl J Med 2007
15


Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
Lindsey A George, Spencer K Sullivan, Adam Giermasz, John E J Rasko, Benjamin J Samelson-Jones, Jonathan Ducore, Adam Cuker, Lisa M Sullivan, Suvankar Majumdar, Jerome Teitel,[...]. N Engl J Med 2017
362
15


Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients.
Shrimati Shetty, Sonal Vora, Bipin Kulkarni, Leenam Mota, Manasi Vijapurkar, Leera Quadros, Kanjaksha Ghosh. Br J Haematol 2007
63
15

The current state and future directions of RNAi-based therapeutics.
Ryan L Setten, John J Rossi, Si-Ping Han. Nat Rev Drug Discov 2019
437
15

RNA-Targeted Therapeutics.
Stanley T Crooke, Joseph L Witztum, C Frank Bennett, Brenda F Baker. Cell Metab 2018
317
13


A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
H Eichler, P Angchaisuksiri, K Kavakli, P Knoebl, J Windyga, V Jiménez-Yuste, A Hyseni, U Friedrich, P Chowdary. J Thromb Haemost 2018
35
17


Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.
Jian-Ming Gu, Xiao-Yan Zhao, Thomas Schwarz, Joachim Schuhmacher, Andreas Baumann, Elena Ho, Babu Subramanyan, Kathy Tran, Timothy Myles, Chandra Patel,[...]. AAPS J 2017
35
17

New therapies for hemophilia.
Angela C Weyand, Steven W Pipe. Blood 2019
68
13

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami. N Engl J Med 2016
244
13


Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Amit C Nathwani, Ulreke M Reiss, Edward G D Tuddenham, Cecilia Rosales, Pratima Chowdary, Jenny McIntosh, Marco Della Peruta, Elsa Lheriteau, Nishal Patel, Deepak Raj,[...]. N Engl J Med 2014
749
13

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.
S M Elbashir, J Harborth, W Lendeckel, A Yalcin, K Weber, T Tuschl. Nature 2001
13


Design and characterization of an APC-specific serpin for the treatment of hemophilia.
Stéphanie G I Polderdijk, Ty E Adams, Lacramioara Ivanciu, Rodney M Camire, Trevor P Baglin, James A Huntington. Blood 2017
84
13

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Thazha P Prakash, Mark J Graham, Jinghua Yu, Rick Carty, Audrey Low, Alfred Chappell, Karsten Schmidt, Chenguang Zhao, Mariam Aghajan, Heather F Murray,[...]. Nucleic Acids Res 2014
299
11


Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Jerry S Powell, K John Pasi, Margaret V Ragni, Margareth C Ozelo, Leonard A Valentino, Johnny N Mahlangu, Neil C Josephson, David Perry, Marilyn J Manco-Johnson, Shashikant Apte,[...]. N Engl J Med 2013
234
11

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Ida Hilden, Brian Lauritzen, Brit Binow Sørensen, Jes Thorn Clausen, Christina Jespersgaard, Berit Olsen Krogh, Andrew Neil Bowler, Jens Breinholt, Albrecht Gruhler, L Anders Svensson,[...]. Blood 2012
99
11

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
Sylvie Boutin, Virginie Monteilhet, Philippe Veron, Christian Leborgne, Olivier Benveniste, Marie Françoise Montus, Carole Masurier. Hum Gene Ther 2010
539
11

In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
R Hartmann, T Feenstra, L Valentino, M Dockal, F Scheiflinger. J Thromb Haemost 2018
44
11

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Johnny Mahlangu, Jerry S Powell, Margaret V Ragni, Pratima Chowdary, Neil C Josephson, Ingrid Pabinger, Hideji Hanabusa, Naresh Gupta, Roshni Kulkarni, Patrick Fogarty,[...]. Blood 2014
313
11

Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Wolfgang Miesbach, Karina Meijer, Michiel Coppens, Peter Kampmann, Robert Klamroth, Roger Schutgens, Marco Tangelder, Giancarlo Castaman, Joachim Schwäble, Halvard Bonig,[...]. Blood 2018
156
11

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.
Jayaprakash K Nair, Husain Attarwala, Alfica Sehgal, Qianfan Wang, Krishna Aluri, Xuemei Zhang, Minggeng Gao, Ju Liu, Ramesh Indrakanti, Sally Schofield,[...]. Nucleic Acids Res 2017
104
11

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
Eliane Sardh, Pauline Harper, Manisha Balwani, Penelope Stein, David Rees, D Montgomery Bissell, Robert Desnick, Charles Parker, John Phillips, Herbert L Bonkovsky,[...]. N Engl J Med 2019
119
11

Targeting activated protein C to treat hemophilia.
Stéphanie G I Polderdijk, Trevor P Baglin, James A Huntington. Curr Opin Hematol 2017
24
20

Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.
Elena Barbon, Gabriel Ayme, Amel Mohamadi, Jean-François Ottavi, Charlotte Kawecki, Caterina Casari, Sebastien Verhenne, Solenne Marmier, Laetitia van Wittenberghe, Severine Charles,[...]. EMBO Mol Med 2020
13
38

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen,[...]. Blood 2019
121
11

Givosiran: First Approval.
Lesley J Scott. Drugs 2020
125
11

Overcoming cellular barriers for RNA therapeutics.
Steven F Dowdy. Nat Biotechnol 2017
443
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.